TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

RNS Number : 8007I
Oxford Biomedica PLC
30 July 2012
 

 


TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi



1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
ii

Oxford Biomedica Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached


An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments


An event changing the breakdown of voting rights


Other (please specify): Update to Total Voting Rights


X

3. Full name of person(s) subject to the
notification obligation:
iii

 

 

M&G Investment Funds 3

4. Full name of shareholder(s)
 (if different from 3.):iv

 

 

State Street Noms Ltd A/C GMIQ

 

 

5. Date of the transaction and date on
which the threshold is crossed or
reached:
v

25 July 2012

6. Date on which issuer notified:

27 July 2012

7. Threshold(s) that is/are crossed or
reached:
vi, vii

See Item 13




 

8. Notified details:

 

A: Voting rights attached to shares viii, ix

 

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

 

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

 

Direct

Direct xi

Indirect xii

Direct

Indirect

 

ORD GBP0.01

GB0006648157

84,331,338

84,331,338

230,311,338

230,311,338


16.35%


 


 

B: Qualifying Financial Instruments

 

Resulting situation after the triggering transaction

 

Type of financial
instrument

Expiration
date
xiii

Exercise/
Conversion Period
xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

 






 


 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

 

Resulting situation after the triggering transaction

 

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period
xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 





 

 

Nominal

Delta




 

Total (A+B+C)

 

Number of voting rights

Percentage of voting rights

 

230,311,338

16.35%

 

 

 

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi


 

 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease
to hold:

N/A

12. Date on which proxy holder will cease to hold
voting rights:

N/A



13. Additional information:

With reference to item 3, M&G Investments Funds 3 is an Open Ended Investment Company (OEIC) and is not a Prudential group company and must be separately disclosed.

This OEIC Fund is managed by M&G Investment Management Limited (a wholly owned subsidiary of Prudential plc) and will have been previously attributed to Prudential plc solely on the basis that M&G Investment Management Ltd has direct fund management control over the shares identified in this notification. 

Therefore the 16.35% holding being disclosed in this notification is encompassed in the 18.32% already disclosed under The Prudential plc group of companies and is NOT in addition to it.

 

14. Contact name:

Tim Watts, Chief Financial Officer

Oxford Biomedica

15. Contact telephone number:

+44 (0) 1865 783 000

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

HOLBGGDRUUXBGDG